Cervical Cancer Market: Epidemiology, Therapies, Companies, DelveInsight | ADC therapeutics, Agenus, Akeso Biopharma, AstraZeneca, Betta Pharmaceuticals, Biocad, Bristol Myers Squibb, Exelixis, Genentech (Roche), Genmab

Cervical Cancer therapies, such as Volrustomig, PRGN-2009, and others, are expected to boost the Cervical Cancer Market in the upcoming years.

DelveInsight has launched a new report on "Cervical Cancer - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Cervical Cancer, historical and forecasted epidemiology as well as the Cervical Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Cervical Cancer market report @ https://www.delveinsight.com/report-store/cervical-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Cervical Cancer Market Report:

The Cervical Cancer market size across the 7MM was approximately USD 930 million in 2023 and is projected to grow at a significant CAGR during the forecast period (2020-2034).
The United States accounted for the largest share of the Cervical Cancer market, with a market size of nearly USD 530 million in 2023.
Cervical cancer is most commonly diagnosed between the ages of 35 and 44, with the average age at diagnosis in the US being 50. More than 20% of cases are identified after age 65, while cases in individuals under 20 are rare.
Over the last two decades, most countries in the 7MM have seen a decline in cervical cancer incidence. In the US, cases declined steadily from the mid-1970s to the mid-2000s due to increased screening. However, SEER data showed a temporary rise in 2021, likely due to the COVID-19 pandemic, before returning to a downward trend.
In the EU4 and the UK, most countries reported a gradual decline in cases, although Spain and the UK maintained relatively stable incidence rates over the past decade.
Despite being a late adopter of HPV vaccination, Japan recorded fewer cases in 2023 compared to 2020, with the national vaccination program resuming in November 2021. It remains to be seen if this will result in a substantial future decline in incidence.
Immunotherapy is emerging as a transformative approach in cervical cancer treatment, with biomarkers expected to play a vital role in identifying patients who may benefit.
KEYTRUDA (pembrolizumab) represents a milestone as the first immune checkpoint inhibitor approved for cervical cancer treatment.
Major companies active in the cervical cancer treatment landscape include Roche, Merck, Bristol Myers Squibb, Advaxis, Zydus, and others developing innovative diagnostics and therapeutics.
In 2023, the total number of incident cervical cancer cases in the 7MM was approximately 40,600, with the United States contributing the highest share.
In February 2024, Pfizer and Genmab announced that the European Medicines Agency (EMA) had validated the marketing authorization application for tisotumab vedotin for adults with recurrent or metastatic cervical cancer who experienced disease progression after first-line therapy.
In January 2024, Merck announced FDA approval for the use of KEYTRUDA in combination with chemoradiotherapy for patients with FIGO 2014 Stage III-IVA cervical cancer, based on results from the Phase III KEYNOTE-A18 trial.
In September 2023, Nykode Therapeutics received FDA approval for its Investigational New Drug (IND) application to initiate a Phase II clinical trial of VB10.16 in combination with Roche's PD-L1 inhibitor, atezolizumab, for HPV16-positive, PD-L1-positive, recurrent or metastatic cervical cancer.
In 2023, the United States accounted for the highest number of incident cervical cancer cases, representing approximately 34% of the total cases across the 7 major markets (7MM).
Within the different histological types of cervical cancer, squamous cell carcinoma made up nearly 9,000 cases in the U.S. during the same year.
In May 2025, the FDA approved the Teal WandTM, developed by Teal Health, making it the first at-home self-collection kit for cervical cancer screening in the U.S.
Key Cervical Cancer companies such as ADC Therapeutics, Agenus, Akeso Biopharma, AstraZeneca, Betta Pharmaceuticals, Biocad, Bristol Myers Squibb, Exelixis, Genentech (Roche), Genmab, and others are evaluating new drugs for Cervical Cancer to improve the treatment landscape.
Promising Cervical Cancer therapies include Volrustomig, PRGN-2009, and others.

Cervical Cancer Overview

Cervical cancer originates in the cells of the cervix, which is the lower, narrow part of the uterus that connects to the vagina (birth canal). The disease typically develops gradually. Initially, cervical cells undergo abnormal changes, known as "atypical cells," which are not yet cancerous. Researchers believe these early changes may mark the beginning of a slow transformation that could eventually lead to cancer. Before becoming cancerous, cervical cells often go through a stage called dysplasia, where abnormal cells start appearing in cervical tissue. If these cells are not treated or removed, they may eventually turn cancerous, grow deeper into the cervix, and potentially spread to nearby areas.

Diagnosing cervical cancer involves multiple steps. The process usually begins with a detailed medical history review and an assessment of any symptoms or risk factors. A physical examination, including a pelvic exam, is then performed to identify any cervical abnormalities. A Pap smear (Pap test) is commonly used to screen for abnormal cervical cells by collecting and examining cell samples under a microscope. In many cases, an HPV test is also conducted to detect the presence of the human papillomavirus, a major risk factor for cervical cancer. If initial screening results are abnormal, further evaluations such as a colposcopy, biopsy, or imaging tests may be conducted to confirm the diagnosis and assess the extent of the disease.

Cervical Cancer Market Outlook

A strong pipeline featuring novel mechanisms of action and a rising incidence rate are key factors propelling growth in the cervical cancer therapeutics market. The evolving pipeline is anticipated to significantly reshape the current treatment landscape, which primarily includes biologics and molecules targeting new therapeutic pathways. Women with unresectable, locally advanced cervical cancer are typically treated with chemoradiotherapy (CRT); however, this approach is associated with long-term toxicities that can negatively impact quality of life. Additionally, recurrences after CRT are often linked to poor outcomes. In recent years, the standard of care for persistent, recurrent, or metastatic cervical cancer has shifted.

While platinum-based chemotherapy combinations have historically been the standard, the preferred first-line regimen now includes cisplatin and paclitaxel combined with bevacizumab, a VEGF-targeting monoclonal antibody. In 2014, the FDA approved Genentech/Roche's AVASTIN (bevacizumab) for use with chemotherapy in patients with advanced cervical cancer, marking a major milestone as the first FDA-approved drug for late-stage cervical cancer since the approval of topotecan with cisplatin in 2006.

The introduction of biosimilars has also significantly influenced the healthcare sector by promoting cost-effective treatment options. In September 2017, the FDA approved Amgen's MVASI as the first cancer therapy biosimilar in the U.S., offering an alternative to Roche's AVASTIN, which was protected by patents until 2019.

Emerging treatment approaches-such as targeted therapies and immunotherapies-are revolutionizing cervical cancer care. Agents like tisotumab vedotin represent significant advancements, while precision medicine continues to drive innovation in both treatment and diagnostics. Leading companies such as AstraZeneca, Roche, Precigen, and Nykode Therapeutics are at the forefront of this progress. Overall, the cervical cancer market is expected to grow steadily during the forecast period (2024-2034).

Discover how the Cervical Cancer market is rising in the coming years @ https://www.delveinsight.com/sample-request/cervical-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Cervical Cancer Marketed Drugs
KEYTRUDA (pembrolizumab): Merck Sharp & Dohme
TIVDAK (Tisotumab vedotin-tftv): Genmab/Pfizer

Cervical Cancer Emerging Drugs

Volrustomig: AstraZeneca
PRGN-2009: Precigen

Scope of the Cervical Cancer Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Cervical Cancer Companies: ADC therapeutics, Agenus, Akeso Biopharma, AstraZeneca, Betta Pharmaceuticals, Biocad, Bristol Myers Squibb, Exelixis, Genentech (Roche), Genmab, and others
Cervical Cancer Therapies: Volrustomig, PRGN-2009, and others.
Cervical Cancer Therapeutic Assessment: Cervical Cancer current marketed and Cervical Cancer emerging therapies
Cervical Cancer Market Dynamics: Cervical Cancer market drivers and Cervical Cancer market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Cervical Cancer Unmet Needs, KOL's views, Analyst's views, Cervical Cancer Market Access and Reimbursement

To know what's more in our Cervical Cancer report, visit https://www.delveinsight.com/report-store/cervical-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Cervical Cancer Market Report:
Cervical Cancer market report covers a descriptive overview and comprehensive insight of the Cervical Cancer Epidemiology and Cervical Cancer market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Cervical Cancer market report provides insights into the current and emerging therapies.
The Cervical Cancer market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Cervical Cancer market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Cervical Cancer market.

Got queries? Click here to know more about the Cervical Cancer market Landscape https://www.delveinsight.com/sample-request/cervical-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Cervical Cancer Patient Share (%) Overview at a Glance
5. Cervical Cancer Market Overview at a Glance
6. Cervical Cancer Disease Background and Overview
7. Cervical Cancer Epidemiology and Patient Population
8. Country-Specific Patient Population of Cervical Cancer
9. Cervical Cancer Current Treatment and Medical Practices
10. Unmet Needs
11. Cervical Cancer Emerging Therapies
12. Cervical Cancer Market Outlook
13. Country-Wise Cervical Cancer Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Cervical Cancer Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Cervical Cancer Market Outlook 2034 https://www.delveinsight.com/report-store/cervical-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Cervical Cancer Pipeline Insights, DelveInsight

"Cervical Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Cervical Cancer market. A detailed picture of the Cervical Cancer pipeline landscape is provided, which includes the disease overview and Cervical Cancer treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.